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a b s t r a c t
The protective effect of a powder of grain (Lisosan G) against cisplatin-induced toxicity in rats was stud-
ied. Male rats were fed with Lisosan G before injection of cisplatin and four days later they were killed
and blood was collected along with hepatic, renal and testicular tissues. The results showed that cisplatin
treatment increased plasma blood urea nitrogen, creatinine and hydrogen peroxide and decreased cyto-
chrome P450 content in renal and hepatic tissues. It also reduced the plasmatic testosterone level and
caused a depletion of testicular 17a-progesterone hydroxylase activity. In the group fed with Lisosan G
and treated with cisplatin blood urea nitrogen and creatinine returned to the control level indicating a
protective effect of Lisosan G. It was also observed that the ones fed with Lisosan G were able to attenuate
the decrease in the P450-dependent activities and the activities of antioxidant enzymes as well. Lisosan G
protected the testicular 17a-progesterone hydroxylase activity and increased the plasma testosterone
level compared to animals treated only with cisplatin. Our results showed a protective effect of Lisosan
G against the cisplatin induced toxicity. The protective effect of Lisosan G could be associated mainly with
the attenuation of the oxidative stress and the preservation in antioxidant enzymes.
 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Cisplatin, cis-diaminedichloroplatinum (II), is one of the most
frequently used anti-neoplastic agents for various types of tumors
(Lebwohl and Canetta, 1998; Taguchi et al., 2005). It has a potent
anti-tumor action against a wide range of malignancies and solid
tumors. Despite its clinical usefulness, cisplatin treatment was
associated with several toxic side effects including nephrotoxicity,
neurotoxicity and ototoxicity (Ali and Al Moundhri, 2006; Chirino
and Pedraza-Chaverri, 2009; Mollman et al., 1988). Although the
mechanism of the side effects induced by cisplatin are not clearly
understood, this drug, in addition to the formation of strong elec-
trophilic intermediates that yield adducts with DNA via nucleo-
philic substitution reactions, causes many alterations of
biochemical parameters in plasma, liver, kidney and testis (Badrel-
din et al., 2006). Besides, many reactive oxygen species are gener-
ated by cisplatin that could interfere with the antioxidant defense
system and result in oxidative damage in the tissues (Badary et al.,
2005).
Various studies from the last decade have shown that the admin-
istration of several antioxidant agents extracted from plants and die-
tary components may reduce some of the side effects of cisplatin
without altering the effects of chemotherapy (Conklin, 2000; Pérez-
Rojas et al., 2009; Sánchez-Pérez et al., 2010). Many examples have
been reported in literature. The treatment with grape seed proanth-
ocyanidin extract, a combination of biologically active bioflavonoids,
prior and post the cisplatin administration protected against the tox-
icity induced by this chemotherapic (Saad et al., 2009; Yousef et al.,
2009). An extract of curcuma comosa, through its antioxidant activ-
ity, revealed a protection against cisplatin-induced nephrotoxicity
(Jariyawat et al., 2009). The caffeic acid phenethyl ester, a flavonoid
present in honey, showed a partial protection on cisplatin-induced
hepatotoxicity and the authors suggested that this effect could be
due to a mechanism other than that relative to its antioxidant prop-
erty (Iraz et al., 2006). Recently it was reported a protection of sulfo-
raphane against cisplatin-induced nephrotoxicity and it was
associated with the attenuation in oxidative/nitrosative stress and
the preservation of antioxidant enzymes (Guerrero-Beltrán et al.,
2010). Previously it was also reported that cereal grains may reduce
the risk of coronary heart disease (Truswell, 2002).
When extracts of plant or natural chemical substances have to
be used during drug-therapy, it is very important to verify that
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they are not able to interact with the drug metabolizing system be-
cause this fact can alter the efficacy of drugs and/or produce ad-
verse events (Ioannides, 1999; Zhou et al., 2004). We have found
that the powder of grain of Triticum Sativum (Lisosan G), used as
nutritional supplement, did not interfere with the phase 1 and 2
drug metabolizing enzymes (Nelson et al., 1996) but had hepato-
protective effects in rats intoxicated by carbon-tetrachloride. In
addition, it has shown a good radical scavenger activity maybe
due at the presence of antioxidant molecules occurring in this
compound; in fact, in Lisosan G there is a good presence of vita-
mins, oligoelements, polyunsaturated fatty acids (Longo et al.,
2007). On the basis of these results it was suggested that Lisosan
G might be co-administrated during drug therapy.
To further support this suggestion, the present study was
undertaken to evaluate whether the administration of Lisosan G
in rats could have a protective effect against toxicity of cisplatin
as measured in plasma, liver, kidney and testis by specific bio-
chemical and enzymatic parameters.
2. Material and methods
2.1. Chemicals
Lisosan G is registered as nutritional supplement by the Italian Minister of
Health and was supplied by Agrisan Company, Larciano (PT), Italy. All other chem-
icals and solvents were of standard brands available on the market.
2.2. Animals and experimental protocol
Sixteen male Wistar rats of 230–250 g were used and the experimental protocol
was approved by the Ethic Committee for Animal care. Rats were divided in four
groups. In the first group (Lis), the rats were fed by Lisosan G for fifteen days; the
second group (Cis) received a single intraperitoneal dose of cisplatin (dissolved in
corn oil) 10 mg/kg and was sacrificed after four days; the third group (Lis+Cis)
was fed with Lisosan G and on the 11th day received a single intraperitoneal dose
of cisplatin 10 mg/kg and sacrificed after four days; the fourth group of rats (con-
trol) was treated with corn oil only. The animals were killed and microsomal and
100,000g supernatant fractions were prepared from the liver, kidney and testis as
previously described (Longo et al., 1991).
2.3. Enzymatic activities
Cytochrome P450 (CYP) content was measured by the method of Omura and
Sato (1964). Aminopyrine-N-demethylase (APD) and Erythromycin-N-demethylase
(ErD) activities were assayed by measuring the formation of formaldehyde (Tu and
Yang, 1983). Ethoxyresorufin-O-deethylase (EROD) activity was determined by
measuring the formation of resorufin spectrofluorimetrically (Lubet et al., 1985).
Ethoxycoumarin-O-deethylase (ECOD) activity was assayed by the fluorimetric
determination of 7-hydroxycoumarin (Aitio, 1978). NAD(P)H:quinone oxidoreduc-
tase (DT-diaphorase) activity was assayed by following the reduction of dichloro-
phenolindophenol at 600 nm and calculating the rate that could be inhibited by
1 lM dicoumarol (Wermuth et al., 1986). Glutathione-S-transferase (GST) activity
was quantified as previously described (Habig et al., 1974) using as substrate 1-
chloro-2,4-dinitrobenzene. The activities of GSSG reductase, and GSH peroxidase
were measured monitoring the consumption of NADPH at 340 nm while the cata-
lase activity was monitored following the H2O2 consumption at 240 nm, as de-
scribed by Cao and Li (2002). Testosterone hydroxylase and progesterone
hydroxylase activities were determined by separating the hydroxylated metabolites
using a Waters 1525 high-performance liquid chromatography apparatus equipped
with a Supelco LC-18 column (250  4.6 mm) as previously reported (Amato et al.,
1996; Swinney et al., 1987). The hydroxylation rates of aniline to 4-aminophenol
were determined using the method of Ko et al. (1987). Serum alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST) activities and testosterone, creati-
nine and BUN contents were measured in plasma according to the instructions of
a commercial kits (Beckman Counter, USA). Hydrogen peroxides were measured
in plasma according to the instructions of a commercial kits (Diacron, Italy).
2.4. Statistical analysis
Results are reported as means ± SD. Significant differences between means of
various rat treatment groups were determined by analysis of variance (ANOVA)
and means were compared using Dunnett’s t-test. All the statistical analyses were
carried out using Prism, GraphPad Software (San Diego, CA, USA).
3. Results
In Fig. 1 the rat plasma values of BUN, creatinine, hydrogen
peroxide and testosterone have been reported. As expected, in
rats treated with cisplatin, a significant increase of plasmatic
BUN and creatinine, hydrogen peroxide, used as measure of oxi-
dative stress, and a remarkable reduction of testosterone levels
were observed. On the contrary, the administration of Lisosan
G did not cause any significant effect on these parameters. The
group of animals fed with Lisosan G and treated with cisplatin
(Lis+cis) showed reduced levels of BUN, creatinine, and hydrogen
peroxide if compared to those of Cis group, indicating that Liso-
san G has a protection with respect to these data in the Cis
group. A protective effect of Lisosan G was also seen in the tes-
tosterone level of the Lis+Cis group which was partially restored
to control level.
In order to investigate the effect of cisplatin on drug metabolis-
ing system, we have measured the CYP content, and the activities
of some CYP-dependent and detoxification enzymes in liver and
kidney tissues.
The hepatic and renal CYP contents in the cisplatin group were
significantly decreased if compared to those of control group,
whereas the co-treatment of cisplatin with Lisosan G restored
the CYP contents to their control values (Fig. 2).
The cisplatin treatment induced also a reduction of the ECOD,
EROD, APD and ErD activities to 20–50% of the corresponding
control values and some of which were totally (EROD) or par-
tially (ECOD) restored by the co-administration of Lisosan G (Ta-
ble 1). In addition, some antioxidant enzymes such as GSH
peroxidase, GSH reductase and catalase, but not GST and DT-
diaphorase, were depleted by cisplatin. The co-administration
of Lisosan G restored the activity of GSH peroxidase and GSH
reductase to the control values whereas the catalase activity
not only recovered but rebound above the value of control group.
It was also noted that the DT-diaphorase activity was not af-
fected by cisplatin but it was found significantly increased in
the Lis+Cis group. The treatment with Lisosan G only did not al-
ter these activities, except catalase, that was significantly
increased.
To further investigate the effect of the various treatments on the
CYP activities, we also determined in liver microsomes the metab-
olism of testosterone (Fig. 3) an endogenous substrate selectively
known to be oxidised by many CYPs (Longo et al., 1991). The tes-
tosterone hydroxylase activities in the positions 2a, 16a and 17,
linked to CYP2C11 (Ryan and Levin, 1990) [the major CYP isoform
constitutively present in male rats liver (Ohishi et al., 1994)], were
decreased significantly by cisplatin treatment and partially recov-
ered with Lisosan G. In addition, the 6b-testosterone hydroxylase,
linked to CYP3A (Ohishi et al., 1994), following cisplatin treatment
was reduced to 40% of the control value and recovered almost en-
tirely in the Lis+Cis group.
In kidney, the treatment with cisplatin reduced significantly the
activities of ECOD, EROD, GST, GSH reductase and catalase, but not
the activity of GSH peroxidase and DT-diaphorase (Table 2). How-
ever, in the Lis+Cis group, the activities of ECOD, EROD and GST
were restored at the control levels, whereas those of GSH reductase
and catalase partially recovered with respect to their control val-
ues. By contrast, the GSH peroxidase activity was not reduced by
cisplatin treatment but resulted to be induced in the rats fed with
only Lisosan G. All the treatments used did not influence the
DT-diaphorase activity in kidney. In Fig. 4 it was reported the
17b-progesterone hydroxylation activity performed in the testis
microsomes. Cisplatin treatment reduced the activity to 20% of
control group value whereas in the group Lis+Cis this activity
partially recovered.
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4. Discussion
The present study evidenced that cisplatin treatment had a
toxic effects on liver, kidney and testis of rats. The elevation of
plasma hydrogen peroxide and hepatic and renal reduction of CYPs
and antioxidant enzymes suggested that the oxidative stress due to
free-radical damage is one of the possible mechanisms in the path-
ophysiology of cisplatin toxicity. In fact oxidative stress and
involvement of oxidative reactive species in cisplatin toxicity have
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Fig. 1. BUN, Creatinine, Testosterone, Hydrogen peroxide levels in the plasma of rats. Values are means ± SD of four experiments performed with plasma of different animals.
*(P < 0,05) **(P < 0.01) ***(P < 0.001) Values differ significantly from the control; (P < 0.001) Values differ significantly from the cisplatin group (ANOVA). Carratelli units:1
CARR U corresponds to 0.8 mg/L hydrogen peroxide.
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Fig. 2. Cytochrome P450 content in microsomes of liver and kidney. Values are
means ± SD of four experiments performed with microsomes of different animals.
**(P < 0.01) Values differ significantly from the control; (P < 0.05) (P < 0.001)
Values differ significantly from the cisplatin group(ANOVA).
Table 1
Cytochrome P450-dependent, phase 2 and antioxidant activities in microsome and
citosol of liver.
C Lis Cis Cis+Lis
ECOD 0.55 ± 0.06 0.69 ± 0.04 0.13 ± 0.09*** 0.3 ± 0.03**,
EROD 0.13 ± 0.02 0.18 ± 0.03 0.07 ± 0.03*** 0.12 ± 0.01
APD 6.8 ± 0.5 7 ± 0.3 2.2 ± 0.3*** 3 ± 0.2***
ErD 1.4 ± 0.3 1.5 ± 0.2 0.6 ± 0.2** 0.5 ± 0.1**
AnH 0.7 ± 0.2 0.8 ± 0.3 0.5 ± 0.2 0.6 ± 0.2
GST 586 ± 79 672 ± 29 499 ± 69 712 ± 50
GSH peroxidase 690 ± 47 745 ± 50 400 ± 20** 800 ± 108
GSH reductase 161 ± 12 156 ± 5 113 ± 6*** 158 ± 7
Catalase^ 475 ± 21 630 ± 20*** 303 ± 28*** 721 ± 20***,
DT-diaphorase 51 ± 15 40 ± 12 71 ± 29 140 ± 47*
The activities are expressed as nmol/mg protein/min. Values are means ± SD of four
experiments performed with microsomes or citosol of different animals.
^ As lmol/mg protein/min.
* (P < 0.05) Values differ significantly from the control.
** (P < 0.01) Values differ significantly from the control.
*** (P < 0.001) Values differ significantly from the control.
 (P < 0.05) Values differ significantly from the cisplatin group (ANOVA).
 (P < 0.01) Values differ significantly from the cisplatin group (ANOVA).
 (P < 0.001) Values differ significantly from the cisplatin group (ANOVA).
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been shown in many studies and were suggested to play an impor-
tant role in the pathogenesis (Badary et al., 2005). In accordance
with previous studies (Baliga et al., 1998; Chirino et al., 2008; Jar-
iyawat et al., 2009) cisplatin treatment developed renal damage
characterized by the increase in BUN and creatinine and a marked
decrease of liver and renal CYP content and of various monooxy-
genase activities. Besides, it reduced the plasma testosterone level
and caused a significant depletion of testicular 17b-progesterone
hydroxylase activity required for androgen biosynthesis. This
activity, catalysed by CYP17, is a key step in testicular steroidogen-
esis (Maines and Mayer, 1985). The effect on this enzymes was re-
ported to be the biochemical basis for the testosterone reduction,
and thought to contribute to infertility observed in patients receiv-
ing cisplatin (Maines and Mayer, 1985). Several free radical scav-
engers and antioxidants including vitamin C, vitamin E and
flavonoids were reported to show some protective effects in cis-
platin-induced toxicity (Badreldin and Al Moundhri, 2006). Lisosan
G is a powder of grain with antioxidant properties due to the pres-
ence of tocopherols, vitamin B1, B2 and B6. The antioxidant activity
of Lisosan G was previously evaluated by the in vitro and in vivo
experiments (Longo et al., 2007). It is known that cisplatin is
mainly nephrotoxic and in this paper the feed with Lisosan G in
combination with cisplatin had an effect renoprotective. In fact
in the animal group Lis+Cis the markers of renal damage such as
BUN and creatinine returned to the control level indicating a pro-
tective effect of Lisosan G. It was observed that the feed with Liso-
san G was able to attenuate the decrease in antioxidant enzymes
provoked by cisplatin. The decrease in the activity of the antioxi-
dant enzymes may be also involved in oxidative stress observed
in cisplatin-treated rats (Koc et al., 2005; Ajith et al., 2007). More-
over our results show that feeding with only Lisosan G induced
antioxidant enzymes such as catalase, gluthatione peroxidase.
These data suggest that in vivo protective effect of Lisosan G was
mediated, at least in part, by the induction and the preservation
of the antioxidant system. In conclusion our results show protec-
tive effect of Lisosan G against the cisplatin induced toxicity. The
underlying mechanisms of Lisosan G could be associated mainly
with the attenuation of the oxidative stress and with the preserva-
tion in antioxidant enzymes. However, further investigation is nec-
essary to demonstrate the exact mechanism of Lisosan G on
cisplatin-induced toxicity.
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Fig. 3. Testosterone hydroxylase activities in hepatic microsomes. Values are
means ± SD of four experiments performed with microsomes or citosol of different
animals. *(P < 0.05) **(P < 0.01) ***(P < 0.001) Values differ significantly from the
control; (P < 0.05) Values differ significantly from the cisplatin group (ANOVA).
Table 2
Cytochrome P450-dependent, phase 2 and antioxidant activities in microsomes and
citosol of kidney.
C Lis Cis Cis+Lis
ECOD^ 5.7 ± 0.8 7 ± 1 1.7 ± 0.5* 8 ± 1.8
EROD^ 1.8 ± 0.6 2.8 ± 0.4 0.14 ± 0.09* 1.2 ± 0.3
GST 106 ± 6 84 ± 10 52 ± 6* 86 ± 10
GSH reductase 217 ± 8 195 ± 6 116 ± 4* 171*,
GSH peroxidase 193 ± 9 294 ± 5* 179 ± 18 295 ± 5*,
Catalase# 140 ± 7 179 ± 21* 44 ± 6* 74 ± 7*,
DT-diaphorase 25 ± 2 23 ± 4 21 ± 3 26 ± 2
The activities are expressed as nmol/mg protein/min. Values are means ± SD of four
experiments performed with microsomes or citosol of different animals.
^ Expressed as pmol/mg protein/min.
# Expressed as lmol/mg protein/min.
* (P < 0.001) Values differ significantly from the control.
 (P < 0.01) Values differ significantly from the cisplatin group (ANOVA).
 (P < 0.001) Values differ significantly from the cisplatin group (ANOVA).
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Fig. 4. 17 b-Progesterone hydroxylase activity in microsomes of testis. Values are means ± SD of four experiments performed with microsomes of different animals.
**(P < 0.01) ***(P < 0.001) Values differ significantly from the control; (P < 0.01) Values differ significantly from the cisplatin group (ANOVA).
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